Headlands Technologies LLC Increases Position in ASP Isotopes Inc. $ASPI

Headlands Technologies LLC grew its holdings in ASP Isotopes Inc. (NASDAQ:ASPI) by 219.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 240,197 shares of the company’s stock after purchasing an additional 165,031 shares during the quarter. Headlands Technologies LLC owned about 0.16% of ASP Isotopes worth $1,494,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Alyeska Investment Group L.P. grew its position in shares of ASP Isotopes by 5.6% in the second quarter. Alyeska Investment Group L.P. now owns 2,843,503 shares of the company’s stock valued at $17,687,000 after purchasing an additional 151,337 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in ASP Isotopes by 43.3% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 161,219 shares of the company’s stock valued at $1,003,000 after acquiring an additional 48,743 shares during the last quarter. Kingsview Wealth Management LLC acquired a new stake in ASP Isotopes during the second quarter worth $337,000. Empowered Funds LLC purchased a new stake in ASP Isotopes in the second quarter valued at $1,400,000. Finally, Philadelphia Financial Management of San Francisco LLC purchased a new stake in ASP Isotopes in the second quarter valued at $8,353,504. 16.80% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Todd Wider sold 50,000 shares of the stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $6.25, for a total transaction of $312,500.00. Following the completion of the sale, the director owned 722,247 shares in the company, valued at approximately $4,514,043.75. This represents a 6.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Robert Ainscow sold 8,438 shares of the firm’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $7.00, for a total value of $59,066.00. Following the transaction, the chief operating officer directly owned 2,281,879 shares in the company, valued at approximately $15,973,153. This represents a 0.37% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 195,321 shares of company stock valued at $1,354,855 in the last quarter. Corporate insiders own 14.40% of the company’s stock.

ASP Isotopes Stock Performance

Shares of ASPI stock opened at $4.02 on Tuesday. The company has a current ratio of 3.87, a quick ratio of 3.85 and a debt-to-equity ratio of 0.76. The firm has a fifty day moving average price of $4.59 and a 200 day moving average price of $5.24. The company has a market cap of $616.31 million, a P/E ratio of -3.05 and a beta of 3.61. ASP Isotopes Inc. has a 12 month low of $3.51 and a 12 month high of $14.49.

ASP Isotopes (NASDAQ:ASPI) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.11). The business had revenue of $5.12 million during the quarter, compared to analyst estimates of $4.47 million. ASP Isotopes had a negative net margin of 427.98% and a negative return on equity of 64.99%.

Analysts Set New Price Targets

ASPI has been the topic of a number of recent analyst reports. Wall Street Zen raised shares of ASP Isotopes from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of ASP Isotopes in a research note on Wednesday, June 24th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $13.00.

ASP Isotopes Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.